Abstract
Leptin has emerged as a major regulator of adiposity. Leptin is released into the blood from fatcells and circulates to the brain where it crosses the bloodbrain barrier (BBB) to act at receptors within the central nervous system to affect appetite, thermogenesis, and a number of other actions. In humansand in many rodent models, resistance to leptin appears to be a chief cause of obesity. Determining the cause of leptin resistance is fundamental to developing strategies for the use of leptin in obesity. Theliterature characterizing the transport of leptin across the BBB is reviewed. This literature stronglysuggests that the cause of leptin resistance is due a decreased transport of leptin across the BBB in obese humans and rodents. The main cause of this resistance appears to be an impairment in the activity of the transporter rather than just simply saturation at higher doses. Strategies to overcome impaired BBB transport are reviewed, including the use of allosteric regulators and the delivery of material by the intrathecal route.
Current Pharmaceutical Design
Title: Leptin Transport Across the Blood-Brain Barrier: Implications for the Cause and Treatment of Obesity
Volume: 7 Issue: 2
Author(s): William A. Banks
Affiliation:
Abstract: Leptin has emerged as a major regulator of adiposity. Leptin is released into the blood from fatcells and circulates to the brain where it crosses the bloodbrain barrier (BBB) to act at receptors within the central nervous system to affect appetite, thermogenesis, and a number of other actions. In humansand in many rodent models, resistance to leptin appears to be a chief cause of obesity. Determining the cause of leptin resistance is fundamental to developing strategies for the use of leptin in obesity. Theliterature characterizing the transport of leptin across the BBB is reviewed. This literature stronglysuggests that the cause of leptin resistance is due a decreased transport of leptin across the BBB in obese humans and rodents. The main cause of this resistance appears to be an impairment in the activity of the transporter rather than just simply saturation at higher doses. Strategies to overcome impaired BBB transport are reviewed, including the use of allosteric regulators and the delivery of material by the intrathecal route.
Export Options
About this article
Cite this article as:
William A. Banks , Leptin Transport Across the Blood-Brain Barrier: Implications for the Cause and Treatment of Obesity, Current Pharmaceutical Design 2001; 7 (2) . https://dx.doi.org/10.2174/1381612013398310
DOI https://dx.doi.org/10.2174/1381612013398310 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MicroRNA Regulation in Cardiovascular Disease
Current Drug Targets Angiogenesis and the Heart
Recent Patents on Cardiovascular Drug Discovery Effects and Perspectives of Chinese Patent Medicines for Tonifying <i>Qi</i> and Promoting Blood Circulation on Patients with Cerebral Infarction
Current Vascular Pharmacology Type 2 Diabetes and Risk for Functional Decline and Disability in Older Persons
Current Diabetes Reviews Simvastatin: Review of Updates on Recent Trends in Pharmacokinetics, Pharmacodynamics, Drug–drug Interaction, Impurities and Analytical Methods
Current Pharmaceutical Analysis Editorial [PCI and Stable Coronary Heart Disease - COURAGE to Change Our Minds?]
Current Vascular Pharmacology Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Functional Foods: Salient Features and Clinical Applications
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Fitness or Fatness: The Debate Continues for AMP-Activated Protein Kinase in Heart Function
Current Cardiology Reviews Biomarker Discovery and Translation in Metabolomics
Current Metabolomics Mast Cells in Allergic and Inflammatory Diseases
Current Pharmaceutical Design Somatic Genome Variations in Health and Disease
Current Genomics Effects of Onion Extract on Endogenous Vascular H2S and Adrenomedulin in Rat Atherosclerosis
Current Pharmaceutical Biotechnology A Journey into the World of Targeted Therapy: A Review of Gene Therapy, Stem Cell Therapy, and Cell Reprogramming in Cardiovascular Medicine
Recent Patents on Regenerative Medicine Food Fortification with Omega-3 Fatty Acids; Microencapsulation as an Addition Method
Current Nutrition & Food Science Extended-release Formulation Attenuates the Impacts of Fluvastatin on Serum PCSK9 Levels in Humans
Letters in Drug Design & Discovery Susceptibility of Periodontopathogenic and Cariogenic Bacteria to Defensins and Potential Therapeutic Use of Defensins in Oral Diseases
Current Pharmaceutical Design Recent Patents on the Upgrading of Fish by-Products
Recent Patents on Chemical Engineering Thrombomodulin Links Coagulation to Inflammation and Immunity
Current Drug Targets Cognitive Function and the Ageing Process: The Peculiar Role of Mild Thyroid Failure
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)